Browsing by Author Tebbutt, Niall

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 35  next >
Issue DateTitleAuthor(s)Citation
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2013An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]Clarke, Stephen; Burge, Matt; Cordwell, Cassandra; Gibbs, Peter; Reece, William; Tebbutt, Niall; Concord Clinical School: MedicineAn Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT], BMC Cancer, vol.13, N/A, 2013,pp 1-7
2012Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin CSimes, Robert John; Tebbutt, Niall; Wilson, Catherine; Zannino, Diana; Ackland, Stephen P.; Broad, A; Cassidy, J; Ganju, V.; Price, Timothy; Robinson, B; Van Hazel, Guy Arthur; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials CentreBevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C, Annals of Oncology, vol.23, 6, 2012,pp 1531-1536
2014Can we accurately report PTEN status in advanced colorectal cancer?Lee, Chee Khoon; Broadbridge, Vy; Cooper, John; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Ruszkiewicz, Andrew; Tebbutt, Niall; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreCan we accurately report PTEN status in advanced colorectal cancer?, BMC Cancer, vol.14, 1, 2014,pp 1-7
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerGebski, Val; Lee, Chee Khoon; Mann, Kristy; Simes, Robert John; Wilson, Kate; Bruhn, M; Cunningham, David; Hardingham, Jennifer; Price, Timothy; Robinson, B; Tebbutt, Niall; Townsend, Amanda; van Hazel, Guy; Weickhardt, Andrew; Wrin, Joseph; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, British Journal of Cancer, vol.112, 6, 2015,pp 963-970
2014Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Pavlakis, Nick; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, J; Tebbutt, Niall; Northern Clinical School: MedicineCurrent opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013, Expert Review of Anticancer Therapy, vol.14, 12, 2014,pp 1477-1493
2015Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literatureChan, David; Pavlakis, Nick; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, J; Tebbutt, Niall; Northern Clinical School: Medicine; Northern Clinical School: MedicineDoes the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature, PloS One, vol.10, 8, 2015,pp 1-17
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerPavlakis, Nick; Azad, Arun; Chong, Geoff; Dobrovic, Alexander; Fluck, Kate; Gebski, Val; Johns, Terrance G; Mariadason, John M; Price, Timothy; Salemi, R; Scott, Andrew M; Skrinos, Effie; Tebbutt, Niall; Weickhardt, Andrew J; Northern Clinical School: MedicineDual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer, Journal of Clinical Oncology, vol.30, 13, 2012,pp 1505-1512
2017Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancerPavlakis, Nick; Wong, Rachel Sze Hui; Chan, David; Herbertson, R; Li, B; Price, Timothy; Segelov, E; Smith, A; Tebbutt, Niall; Northern Clinical School: Medicine; MedicineEpidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer, Cochrane Database of Systematic Reviews, vol.2017, 6, 2017,pp 1-175
2014Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancerSimes, Robert John; et al, Various; Harbison, C; Jonker, Derek J.; Karapetis, Christos (Chris); Langer, C; Malone, DP; O’Callaghan, C; Price, Timothy; Shapiro, J; Tebbutt, Niall; Tu, Dongsheng; School of Public Health: NH&MRC Clinical Trials CentreEpiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer, British Journal of Cancer, vol.110, 3, 2014,pp 648-655
2014Final results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidinesFournier, Marion; Gebski, Val; Simes, Robert John; Wilson, Kate; Ferry, David; Gordon, Stuart; Karapetis, Christos; Price, Timothy; Ransom, David; Tebbutt, Niall; Yip, Desmond; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFinal results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines, Annals of Oncology, vol.25, 1, 2014,pp 117-121